Baker Bros Deployed $6.9B Into Pure Biotech in One Quarter: Inside the $17B Healthcare-Only Portfolio That Owns Zero Tech Stocks

In a single quarter, Baker Bros. Advisors injected $6.9 billion into pure biotech and pharma names — not a single dollar into technology, financials, or anything outside healthcare. The New York–based fund surged 67.8% to $17.08 billion in Q4 2025, adding 19 new positions while maintaining something almost unheard-of among multi-billion-dollar institutional portfolios: a 100% allocation to a single sector. While every mega-fund from Citadel to Millennium diversifies across tech, energy, and financials, Baker Bros. runs the largest pure-play biotech book in 13F filing history — and this quarter, they doubled down on that bet harder than ever.

TL;DR — Baker Bros. Q4 2025 in 10 Bullets

• AUM: $17.08B, up 67.8% from $10.18B in Q3 2025 — the largest single-quarter jump in the fund's history
• New Capital Deployed: $6.9B injected across 19 new biotech/pharma positions
• Holdings Count: 86 positions, up from 67 in Q3 — 19 net additions
• Top Position: Incyte (INCY) at $3.04B (17.8%) — overtook BeOne as #1
• Sector Allocation: 100% healthcare/biotech — zero tech, zero financials, zero everything else
• Concentration Shift: Top-2 concentration diluted from 55.1% to 33.5% as $6.9B spread across new names
• Biggest New Entries: Madrigal (MDGL) $1.25B, Insmed (INSM) $1.15B, ACADIA (ACAD) $1.15B
• Quarterly Return: +15.98% on existing positions before new capital
• V-Shaped Recovery: Fund dropped from $18.4B to $7.8B trough (2023-24), now back to $17.1B
• Portfolio Thesis: Every holding targets oncology, rare disease, CNS, or metabolic disorders — no platform tech, no diagnostics, no healthcare IT

What $6.9 Billion in Biotech Capital Bought

Baker Bros. didn't just add a few small positions at the margin. Three of the 19 new entries immediately landed in the top 10 with over $1 billion each — the kind of conviction sizing that signals months of due diligence, not opportunistic trading.

Madrigal Pharmaceuticals (MDGL) — $1.25B Entry

Madrigal Pharmaceuticals entered as the fund's third-largest holding at $1.25B (7.3% of portfolio). The company's Rezdiffra became the first FDA-approved treatment for NASH/MASH (metabolic dysfunction-associated steatohepatitis) in March 2024 — a condition affecting an estimated 6-8 million Americans with significant liver fibrosis. Baker Bros.' $1.25B first-time position signals they see Rezdiffra's commercial ramp as still in early innings, with peak sales estimates ranging from $3B to $5B annually across Wall Street.

Insmed (INSM) — $1.15B Entry

Insmed arrived at $1.15B (6.7%), with Baker Bros. accumulating 6.6 million shares. Insmed's Arikayce treats Mycobacterium avium complex (MAC) lung disease, a rare pulmonary condition, while the company's brensocatib pipeline targets bronchiectasis — a potential blockbuster indication with limited competition. The billion-dollar entry suggests Baker Bros. sees the rare disease commercial engine plus pipeline optionality as deeply undervalued.

ACADIA Pharmaceuticals (ACAD) — $1.15B Entry

ACADIA Pharmaceuticals was perhaps the most aggressive new position at 42.9 million shares worth $1.15B (6.7%). That share count — roughly 4x the typical institutional position size — reflects the concentrated conviction Baker Bros. brings to CNS/neuroscience. ACADIA's Nuplazid treats Parkinson's disease psychosis, while their trofinetide (Daybue) addresses Rett syndrome, giving the position exposure to two distinct neurological franchises.

Kymera Therapeutics (KYMR) — $674M Entry

Kymera Therapeutics entered at $674M (3.9%), representing a bet on targeted protein degradation — a next-generation approach to drugging previously "undruggable" targets. At $674M, this is one of the larger institutional positions in Kymera's float, signaling Baker Bros. sees the degrader platform as a potential pillar of next-decade oncology and immunology pipelines.

Other Notable New Positions

Beyond the billion-dollar entries, Baker Bros. seeded positions across the biotech spectrum: mid-cap specialty pharma, clinical-stage oncology, and rare disease names. The 19 new positions collectively account for roughly $5B+ of the $6.9B AUM increase, with the remainder coming from appreciation on existing holdings boosted by the fund's +15.98% quarterly return.

The Concentration Shift — From Two-Stock Fund to Diversified Biotech

Perhaps the most overlooked story in Baker Bros.' Q4 filing is how radically the portfolio structure changed — not because they sold their top holdings, but because $6.9 billion in new capital mechanically diluted everything.

In Q3 2025, BeOne Medicines (ONC) and Incyte (INCY) together comprised 55.1% of the entire portfolio — a staggering concentration that meant more than half the fund's performance was determined by just two biotech stocks. By Q4, that same pair dropped to 33.5% — still the top two holdings, but now sitting within a much broader base of 86 positions.

This isn't a loss of conviction. Baker Bros. didn't trim ONC or INCY. BeOne's share count remained essentially flat at 8.8M shares, and Incyte's 30.7M shares continued to grow. The dilution is entirely structural: when you add $6.9B of new capital, every existing position's weight shrinks proportionally. The result is a fund that went from dangerously concentrated to strategically diversified — without selling a single share of their top convictions.

The top-10 concentration tells the same story: 74.4% of $17.08B sits in ten names, but four of those ten (MDGL, INSM, ACAD, KYMR) didn't exist in the portfolio three months ago. Baker Bros. effectively built a second portfolio on top of their existing one.

The V-Shaped Recovery — From $8.8B Trough to $17.1B

The AUM history chart reveals one of the most dramatic recoveries in institutional 13F data. Baker Bros. spent 2022 through early 2023 managing $17-18 billion with steady returns across 100+ holdings. Then came Q4 2023: the fund's AUM was cut nearly in half, plunging from $17.35B to $8.79B in a single quarter — a 49.3% drawdown that coincided with broader biotech sector weakness and what appeared to be significant investor redemptions.

The trough deepened through mid-2024, bottoming at $7.83B in Q2 2024 — a 57% decline from the Q1 2023 peak of $18.38B. For a fund that had been a biotech juggernaut for over two decades, it was a crisis-level drawdown.

What followed was a methodical rebuild. Holdings were pruned from 95 to 67 between Q4 2024 and Q3 2025 — Baker Bros. was concentrating their surviving capital into their highest-conviction names, cutting underperformers, and preparing the portfolio for a reload. Then Q4 2025 happened: $6.9B of fresh capital flooded in, 19 new positions were established, and the fund rocketed back to $17.08B — within striking distance of its all-time high.

The pattern suggests a deliberate strategy: contract during sector weakness, concentrate into winners, then aggressively re-deploy when conviction and capital align. The Q4 2025 filing is the "re-deploy" moment — Baker Bros. signaling to the market that they believe biotech is entering an up-cycle worth betting $17 billion on.

What Analysts Might Misread — 100% Biotech Is the Strategy, Not a Risk

Traditional portfolio analysis would flag Baker Bros.' 100% healthcare allocation as a concentration risk. No technology exposure. No financial sector hedge. No energy or consumer staples diversification. By conventional standards, this is an unbalanced portfolio.

But that reading fundamentally misunderstands Baker Bros.' value proposition. Julian and Felix Baker founded the firm in 2000 with a singular thesis: deep scientific expertise in drug development creates an informational edge that generalist funds cannot replicate. Every analyst at Baker Bros. evaluates clinical trial data, FDA regulatory pathways, and molecular biology — the kind of due diligence that requires PhD-level domain knowledge.

The result is a portfolio where every position is selected through a scientific lens that most institutional investors simply cannot match. When Baker Bros. puts $1.25B into Madrigal, they're not making a sector bet — they're making a specific assessment of Rezdiffra's phase 3 fibrosis data, commercial adoption curves, and competitive positioning against Novo Nordisk's GLP-1 overlap thesis. That depth of analysis across 86 positions is the fund's moat.

The Q4 2025 filing also reveals interesting sub-sector diversification within biotech. Rather than concentrating in one therapeutic area, Baker Bros.' top 10 spans:

• Oncology: INCY, CELC, RVMD, KYMR (hematologic + solid tumor + protein degradation)
• Rare Disease: INSM, RYTM (pulmonary + metabolic)
• NASH/Metabolic: MDGL (liver disease)
• CNS/Neuroscience: ACAD (Parkinson's + Rett syndrome)
• Immuno-Oncology: SMMT, ONC (checkpoint + targeted)

That's five distinct drug development paradigms within a single sector — arguably more diversified at the thesis level than a generalist fund that owns Apple, Microsoft, and Alphabet and calls it "tech diversification."

Frequently Asked Questions

Why did Baker Bros.' AUM jump 67.8% in a single quarter?

The $6.9B increase came primarily from new capital inflows (likely a combination of new investor allocations and recycled gains) rather than pure market appreciation. The fund's +15.98% quarterly return accounts for roughly $1.6B of the increase; the remaining ~$5.3B represents fresh capital deployed into 19 new positions. This kind of single-quarter capital injection is rare among biotech-focused funds and signals strong investor appetite for Baker Bros.' strategy heading into 2026.

Is Baker Bros. the largest biotech-only fund in 13F filings?

At $17.08B with 100% healthcare allocation, Baker Bros. is almost certainly the largest pure-play biotech/pharma portfolio reported in SEC 13F filings. Other large healthcare investors like OrbiMed, RA Capital, and Perceptive Advisors manage significant biotech books, but none approach Baker Bros.' combination of AUM scale and complete sector exclusivity. Generalist funds like Citadel or Point72 may hold more total biotech by dollar value, but those positions sit within diversified portfolios spanning every sector.

Why did Incyte overtake BeOne as the #1 position?

Incyte rose from $2.61B (25.6%) in Q3 to $3.04B (17.8%) in Q4, while BeOne Medicines fell from $3.00B (29.5%) to $2.67B (15.7%). The share counts remained relatively stable for both, so the swap was driven by relative stock price performance — Incyte appreciated while BeOne pulled back. Notably, both positions' portfolio weight dropped significantly (Incyte from 25.6% to 17.8%, BeOne from 29.5% to 15.7%) purely because the $6.9B in new capital expanded the denominator.

What happened during the 2023-2024 AUM crash?

Baker Bros.' AUM fell from $18.38B in Q1 2023 to a trough of $7.83B in Q2 2024 — a 57% decline over five quarters. This coincided with a brutal period for biotech: rising interest rates crushed long-duration biotech valuations, the XBI biotech ETF underperformed the S&P 500 significantly, and several Baker Bros. portfolio companies faced clinical trial setbacks. The magnitude of the decline suggests investor redemptions compounded market losses. The fund responded by concentrating: holdings dropped from 107 to 67 as they trimmed weaker positions and doubled down on survivors.

Should retail investors follow Baker Bros. into these biotech names?

Baker Bros.' 13F filing is a valuable signal of deep scientific conviction, but retail investors should understand the context. These positions were built over weeks or months with institutional-scale due diligence on clinical data, regulatory timelines, and competitive landscapes. By the time the Q4 2025 filing was published on February 17, 2026 — 48 days after the December 31 reporting date — stock prices may have already moved significantly. The filing is best used as a screening tool to identify names worth your own research, not as a real-time buy list. Consider the 13F a starting point for understanding where elite biotech specialists see value, then do your own due diligence on individual names.

How does Baker Bros.' Q4 2025 portfolio compare to its 2022 peak?

The $17.08B AUM is essentially back to 2022 levels ($17.4-17.6B range), but the portfolio composition is markedly different. In 2022, Baker Bros. held 115-118 positions with a more distributed weight curve. Today's 86-position portfolio is more concentrated in the top 10 (74.4%) and includes several names — MDGL, INSM, ACAD, KYMR — that weren't in the portfolio at all during 2022. The fund rebuilt from the ground up rather than simply recovering old positions, suggesting the Bakers see a fundamentally different biotech landscape in 2025-2026 than they did three years ago.